Work Here?
Work Here?
Work Here?
Verve Therapeutics focuses on developing gene editing treatments for cardiovascular disease. Their approach involves creating single-course therapies that aim to provide lasting solutions rather than ongoing treatments. The company specifically targets the PCSK9 and ANGPTL3 genes, which are known to help lower blood lipid levels. This focus on gene editing sets Verve apart from traditional therapies that require continuous management. The goal of Verve Therapeutics is to offer potentially curative options for patients with cardiovascular conditions, improving their long-term health outcomes.
Company Stage
IPO
Employees
201-500
Industries
Biotechnology, Healthcare
Total Funding
$353.6M
Headquarters
Cambridge, Massachusetts
Founded
2018
Help us improve and share your feedback! Did you find this helpful?
Find jobs on Simplify and start your career today